1. Abstract 4927: Plasma and CNS pharmacokinetics of the CHK-1 inhibitor prexasertib (LY-2606368) in mice bearing orthotopic group 3 medulloblastoma
- Author
-
Clinton F. Stewart, Anil R. Maharaj, Abigail D. Davis, Martine F. Roussel, and Bo Zhong
- Subjects
Medulloblastoma ,Cancer Research ,Mesylate ,Cancer ,Pharmacology ,medicine.disease ,In vitro ,NONMEM ,chemistry.chemical_compound ,Oncology ,chemistry ,Pharmacokinetics ,medicine ,Bioluminescence imaging ,Protein kinase A - Abstract
Many children with brain tumors have limited treatment options and poor long-term survival. A key protein kinase involved in activating and maintaining the S and G2/M checkpoints is CHK1, which when inhibited in the absence of p53 leads to loss of DNA damage checkpoints and can enhance the activity of many DNA-damaging agents. Prexasertib (LY-2606368), a potent and selective small molecule inhibitor of CHK1 protein kinase activity in vitro (IC50 Citation Format: Anil Maharaj, Abigail Davis, Bo Zhong, Martine F. Roussel, Clinton F. Stewart. Plasma and CNS pharmacokinetics of the CHK-1 inhibitor prexasertib (LY-2606368) in mice bearing orthotopic group 3 medulloblastoma [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2018; 2018 Apr 14-18; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2018;78(13 Suppl):Abstract nr 4927.
- Published
- 2018
- Full Text
- View/download PDF